Company Description
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.
In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China.
The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3.
Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 5, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,965 |
| CEO | Ying Huang |
Contact Details
Address: 2101 Cottontail Lane Somerset, New Jersey 08873 United States | |
| Phone | 737 317 5050 |
| Website | legendbiotech.com |
Stock Details
| Ticker Symbol | LEGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 1801198 |
| CUSIP Number | 52490G102 |
| ISIN Number | US52490G1022 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jessie Yeung M.B.A. | Vice President of Finance, Investor and Public Relations |
| James Pepin J.D. | General Counsel |
| Ananda Elizabeth Martin Esq. | Global Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 10, 2026 | 6-K | Report of foreign issuer |
| Feb 6, 2026 | 6-K | Report of foreign issuer |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Jan 23, 2026 | 6-K | Report of foreign issuer |
| Jan 21, 2026 | 6-K | Report of foreign issuer |
| Jan 14, 2026 | 6-K | Report of foreign issuer |
| Jan 12, 2026 | 6-K | Report of foreign issuer |
| Dec 29, 2025 | 144 | Filing |
| Dec 29, 2025 | 144 | Filing |